Monitor for potential dilution impact from the 2,000 warrants per unit (implying ~3.6 million new shares if fully exercised); assess whether this capital extends runway meaningfully for clinical development given the company's small size and speculative stage.
Price Chart
Executive Summary
AIM ImmunoTech Inc. closed a $1.8 million rights offering, issuing units consisting of Series G Convertible Preferred Stock and warrants to purchase common stock at $1,000 per unit. The capital raise, facilitated by Maxim Group LLC, provides limited funding for a company with a $3M market cap focused on developing Ampligen for late-stage pancreatic cancer, though no clinical or financial performance data was disclosed.
Key Financial Metrics
Key Facts
- AIM ImmunoTech closed a rights offering raising approximately $1.8 million.
- Each unit sold consisted of one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, priced at $1,000 per unit.
- Maxim Group LLC acted as dealer-manager.
- The offering was registered under SEC Form S-1 (No. 333-292085), declared effective February 10, 2026, with a prospectus supplement filed February 27, 2026.
- No revenue, earnings, or clinical trial results were disclosed in the release.
Financial Impact
$1.8 million raised through a rights offering; structure includes significant warrant overhang (3.6 million new warrant shares implied).
Risk Factors
- High dilution risk from warrant overhang if exercised.
- No clinical or revenue milestones disclosed; company remains pre-revenue with unproven therapeutic.
- Funds may be insufficient to advance Ampligen through pivotal trials without further raises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251368 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers